

MOLNUPIRAVIR (Capsules 200 mg)

Thank you for taking part in the PANORAMIC Trial. Here is some information about the trial treatment you have been given.

The treatment you have been given is called **molnupiravir**, a new antiviral treatment. The treatment has a conditional license, which means that it has been licensed for use based on less data than normally required. To receive this licence, the data has shown that the treatment's benefits outweigh the risks.

You need to take your trial medication for **5 days**.

Dose and Administration:

- **Molnupiravir** capsules (200 mg) are for oral administration.
- Four capsules of molnupiravir are to be taken twice a day, twelve hours apart (For example, first daily dose at 8:00 am, second daily dose at 8.00 pm).
- The medication is taken for five days.
- If you miss a dose, take the missed dose as soon as you remember **BUT** skip the missed dose if it is almost time for your next scheduled dose.
- If a dose is missed **DO NOT** take extra medication when you have your next scheduled dose.

Pregnancy Test:

Participants of childbearing potential (i.e., participants who are physically able to become pregnant regardless of their current contraception methods or relationship status) must have a negative pregnancy test result prior to starting trial treatment.

- If you are a person of childbearing potential, you must complete the urine pregnancy test enclosed with your participant pack and have a **negative test result, before** you start treatment. Instructions for how to take the pregnancy test are enclosed with the test.
- Please take the pregnancy test as soon as you receive your participant pack, which must be **before you start the medication**.
- If the pregnancy test is negative, please start your medication.
- If the test result is positive, you **MUST NOT** take the medication. Please contact the trial team: 08081 560017.
- One of the trial doctors or research nurses will explain this process to you before you start the trial. They will also call you on Day 1 (the day after enrolling you into the trial) to confirm that you have received your participant pack, taken the pregnancy test, and that the result is negative. If the result is positive, we will withdraw you from the trial and you will be asked to return all medication by a courier arranged by the trial team.

Contraception:

- If you are of childbearing potential and in a heterosexual relationship, you must also use highly effective contraceptives for the 28-day duration of the trial:

*The implant, the coil and male or female sterilisation will be acceptable for the trial. The injection and most forms of hormonal contraception will also be deemed acceptable for the trial if used in combination with condoms or other barrier methods. However, condoms alone won't be sufficient during the trial. Abstinence will also be considered as a form of contraception if you have been abstinent for the 28 days before enrolling in the trial and will continue to be abstinent for the 28-day duration of follow-up. Abstinence is defined as being in line with the preferred and usual lifestyle of the participant. You can discuss any questions you have about contraception during the study period with the trial team. **It is important to note that a barrier method on its own is not sufficient.***

- **If you were to become pregnant during the trial you must tell us immediately and you will be withdrawn from the trial, although we will ask to follow you up for safety reasons.**

Side-Effects

Common side effects include dizziness, headache, diarrhoea, and nausea.

You will be able to tell us if you are experiencing these and any other side-effects in your daily diary and these will be monitored by a group of medically trained doctors, to ensure your safety. Your GP, a trial doctor or research nurse will also call you on **Day 2** (the day after receiving your participant pack and starting your medication) to check whether you have experienced any side-effects since starting your medication.

If you experience side-effects after taking the trial treatment, and you would like to speak to a trial doctor or nurse, please call the 24-hour telephone line: 0808 168 0130.

Precautions

Please do not take the treatment if you have a known allergy to molnupiravir or you are currently taking molnupiravir.

This treatment can cause rare allergic reactions. **If you develop any problems, please stop taking the treatment immediately and seek medical advice.**

If a medical emergency related to your antiviral treatment occurs while you are at home, you should contact 111, 999, or go to the accident and emergency (A&E) department at your local hospital.

Storage

Please store the treatment in a dry area, at room temperature (15° to 30°C/59° to 86°F), out of direct light.

Please remember that you should not be taking any other medications other than your usual prescribed medication and the treatment you have been given for the trial.

Medication Return



If you decide that you no longer wish to take the treatment, please let the trial team know either by phone 08081 560017, or email: panoramic@phc.ox.ac.uk. Please confirm when you speak to one of the team, or in your email message, how many tablets will be returned. You will be sent a pre-paid envelope to return the tablets. This will need to be dropped off at a post office as and when it is possible for you (or someone on your behalf) to take it to one. This will allow the return to be tracked.